Meet Hal Leshner, first-time hiker in the CF Foundation's Xtreme Hike, a fundraising event that challenges members of the CF community, and their families and friends, to take on the great outdoors.
Site Search
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Meet a few faces from the 2015 Pittsburgh's 50 Finest event and learn how they raised funds and awareness for the CF cause.
This year our CF Foundation employee Great Strides team adopted a “Star Wars” theme and, believe me, we went all out to make the experience extra special and out of this world. See for yourself!
Ever wonder, “Does my donation matter?” Jodi Marquez-Klarenbeek is living proof of the collective power of raising funds. This Giving Tuesday, give to an organization that's changing lives today.
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations